Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385177 | 1.00 | GRIA2 (0.51) | GRIA2KDM4EALDH1A1LMNACYP3A4 | |
| SCHEMBL1817775 | 0.85 | CYP1A2 (0.61) | GRIA2ALDH1A1TSHRPTPRAHPGD | |
| SCHEMBL1817774 | 0.85 | CYP1A2 (0.61) | GRIA2ALDH1A1TSHRPTPRAHPGD | |
| SCHEMBL30959758 | 0.85 | CYP1A2 (0.61) | GRIA2ALDH1A1TSHRPTPRAHPGD | |
| SCHEMBL2127356 | 0.84 | GRIA2 (0.50) | GRIA2KDM4EALDH1A1LMNACYP3A4 | |
| SCHEMBL17002633 | 0.84 | GRIA2 (0.50) | GRIA2KDM4EALDH1A1LMNACYP3A4 | |
| SCHEMBL652018 | 0.84 | GRIA2 (0.56) | GRIA2ALDH1A1CYP3A4ALOX15KMT2A | |
| SCHEMBL11266099 | 0.83 | ALOX15 (0.44) | ALOX15HSD17B10L3MBTL1CYP1A2 | |
| SCHEMBL29054253 | 0.82 | GRIA2 (0.44) | GRIA2KDM4EALDH1A1LMNACYP3A4 | |
| SCHEMBL29054255 | 0.82 | GRIA2 (0.44) | GRIA2KDM4EALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110922469-B | Method for inhibiting human calcitonin aggregation | 华中科技大学 | 2021-04-20 | — | — | CN | claimed |
| CN-110922469-A | Method for inhibiting human calcitonin aggregation | 华中科技大学 | 2020-03-27 | — | — | CN | claimed |
| EP-1991572-A2 | PEPTIDES THAT BLOCK THE BINDING OF IGG TO FCRN | SYNTONIX PHARMACEUTICALS, INC. (US) | 2008-11-19 | — | — | EP | claimed |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | BIOGEN HEMOPHILIA INC. | 2007-11-01 | — | — | US | claimed |
| WO-2007098420-A2 | PEPTIDES THAT BLOCK THE BINDING OF IGG TO FCRN | SYNTONIX PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | claimed |
| EP-4651906-A1 | ANTI-CD70 ANTIBODY-DRUG CONJUGATES | Ambrx, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4598586-A1 | DRUG LINKERS AND ANTIBODY CONJUGATES THEREOF | Ambrx, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-3541829-B1 | SUBSTANCES FOR TARGETING VARIOUS SELECTED ORGANS OR TISSUES | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025041055-A1 | ANTI-PSMA ADC CONJUGATE COMPOSITIONS AND METHODS OF USE THEREOF | AMBRX, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| WO-2024155627-A1 | ANTI-CD70 ANTIBODY-DRUG CONJUGATES | AMBRX, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| WO-2024077277-A1 | DRUG LINKERS AND ANTIBODY CONJUGATES THEREOF | AMBRX, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-11459358-B2 | Substances for targeting various selected organs or tissues | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2022-10-04 | — | — | US | disclosed |
| US-20080234183-A1 | Cell Penetrating Peptides | CEPEP II AB (SE) | 2008-09-25 | — | — | US | disclosed |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | BIOGEN HEMOPHILIA INC. | 2007-11-01 | — | — | US | disclosed |
| WO-2007098420-A2 | PEPTIDES THAT BLOCK THE BINDING OF IGG TO FCRN | SYNTONIX PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| EP-1516184-B1 | Cell-selective delivery system | CEPEP II AB (SE) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006017619-A2 | RECEPTOR-BINDING CYCLIC PEPTIDES AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060029544-A1 | Receptor-binding cyclic peptides and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2006-02-09 | — | — | US | disclosed |
| EP-1516184-A2 | CELL PENETRATING PEPTIDES | CePeP AB (SE) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003106491-A2 | CELL PENETRATING PEPTIDES | CEPEP AB (SE) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | FCGRT, FCGR3B, FCGR1A | GRIA2 741/4885KDM4E 4111/4885ALDH1A1 4835/4885 |
| US-20060029544-A1 | Receptor-binding cyclic peptides and methods of use | ITGB3, ITGB5, ITGA5 | GRIA2 991/4885KDM4E 3616/4885ALDH1A1 4662/4885 |
| US-20080234183-A1 | Cell Penetrating Peptides | VIP, TAP1, CPA3 | GRIA2 4066/4885KDM4E 4173/4885ALDH1A1 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.